Drugs / Extract of Ginkgo Biloba
Extract of Ginkgo Biloba
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00672373 | Dec 2006 → May 2007 | schizophrenia, tardive dyskinesia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05906199 | Jul 2021 → Jun 2023 | diabetic peripheral angiopathy | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | extract of Ginkgo biloba | “We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention...” PMID 40803668 ↗ Aug 2025 |
| Known as | EGb | “We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention...” PMID 40803668 ↗ Aug 2025 |
| Known as | EGb-761 | “Extract of Ginkgo Biloba (EGb-761 capsules)” NCT00672373 ↗ |
| Route | Oral | “tid,po” NCT00672373 ↗ |